Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Unresectable Melanoma: early-phase trial registry
8 of 25 indexed Unresectable Melanoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #652 of 28,707 conditions by registered trial count.
25 US clinical trials · 8 currently recruiting · #652 of 28,707 conditions by registered trial count
Unresectable Melanoma: 25 US clinical trials tracked, 8 recruiting.
Unresectable Melanoma is the subject of 25 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 7 of these trials.
Enrollment posture brief
Registry condition unresectable-melanoma
OPEN 8 | RECR 32% | LATE 3 | EARLY 21 | RANK #652 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Shoulder Pain (32% recruiting · 28 trials)
Unresectable Melanoma lists 8 open slots (32% of 25 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Unresectable Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Unresectable Melanoma is recruiting below its size-band peers.
8 of 25 indexed trials (32%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Unresectable Melanoma research.
National Cancer Institute (NCI) accounts for 7 of 25 trials (28%). 14 distinct sponsors appear on at least one study for this condition label.
-
Typical Unresectable Melanoma enrolment sits around 94 participants.
Median target enrolment is 94 among the 25 trials that report a genuine target (sentinel values excluded). 13 of those (52%) plan for fewer than 100 participants.
-
Unresectable Melanoma research is mostly interventional.
24 interventional and 1 observational studies make up this index (96% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
25 total, page 1 of 1
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Iovance Biotherapeutics
NCT05727904
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics
NCT06624644
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
NCT05428007
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
Iovance Biotherapeutics
NCT07288203
Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma
M.D. Anderson Cancer Center
NCT06466434
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Iovance Biotherapeutics
NCT05361174
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Iovance Biotherapeutics
NCT06940739
Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
University of Wisconsin, Madison
NCT06199713
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
IO Biotech
NCT05155254
Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread
National Cancer Institute (NCI)
NCT02196181
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
National Cancer Institute (NCI)
NCT02224781
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT01134614
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
ECOG-ACRIN Cancer Research Group
NCT04462406
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
NCT01989585
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
M.D. Anderson Cancer Center
NCT02910700
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
M.D. Anderson Cancer Center
NCT04645680
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
National Cancer Institute (NCI)
NCT02965716
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Mayo Clinic
NCT03021460
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT05628883
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
Emory University
NCT03719131
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
NCT04616248
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
BioNTech SE
NCT04526899
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT01950390
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
Incyte Corporation
NCT03679767
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma
National Cancer Institute (NCI)
NCT03033576
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 15 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Unresectable Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Unresectable Melanoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Unresectable Melanoma page
25 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Unresectable Melanoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Unresectable Melanoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Unresectable Melanoma condition card totals 25 registered trials; most-linked intervention Ipilimumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.